User login
Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).
Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).
Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.
Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.
Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi: 10.1155/2022/4433313
Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).
Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).
Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.
Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.
Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi: 10.1155/2022/4433313
Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).
Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).
Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.
Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.
Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi: 10.1155/2022/4433313